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ABSTRACT
Background: Hepatitis C virus (HCV) is now recognized as the cause of 90% of non-A, non-B
(NANB) hepatitis. This virus is responsible for a large percentage of chronic persistent and chronic
active hepatitis in the United States. Parenteral and sexual transmission are well described, so a
significant population of pregnant patients is at risk. Vertical transmission of the virus to the fetus
is dependent upon the level of maternal viremia.
Case:The eases described in the following report demonstrate that fulminant disease may present
in pregnancy. They also demonstrate the eofaetors promoting the severity of illness, methods of
diagnosis, potential treatment, and outcome of the infection.
Conclusion: HCV may be encountered in pregnancy. Although most acute-phase illness will be
self limiting, some patients will manifest liver failure during gestation. Because vertical transmission
to the fetus is possible, the pediatrician should be informed of the maternal disease. Chronic hepatitis
is almost the rule rather than the exception, so patients require dose postpartum follow-up. Inter-
feron, which may alter the course of the chronic disease, has been used on rare occasions in
pregnancy. (C) 1996 Wiley-Liss, Inc.
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he hepatitis C virus (HCV) is now recognized
as one of the leading causes of chronic liver
disease and cirrhosis throughout the world. The
identification of the viral genome has led to the
awareness that, although almost all post-transfusion
hepatitis cases are the result of this agent, a blood
transfusion is not the major source of the disease.
Two cases of HCV infection in pregnancy are pre-
sented along with a discussion of the pathogenesis,




The patient was a 34-year-old GeP1 with an esti-
mated gestational age at admission of 34 weeks.
Eight days prior to her admission, she noted the
onset ofwatery stool and mild epigastric pain. Other
signs included dark urine and jaundice on the day
prior to her admission. She denied any medication,
alcohol, or toxin exposure or household contacts
with hepatitis. Her physical examination at admis-
sion was significant for a blood pressure of 100/60
and a temperature of 36.2C. Her sclera were icteric
and her skin was deeply jaundiced. Her abdomen
was nontender with no hepatomegaly. Her admis-
sion laboratory values included an AST of 1,195
(normal range 3-50 IU/1), ALT of 796 (normal range
9-52 IU/1), and total bilirubin of 5.9 (normal range
0.2-1.3 mg/dl). Additional laboratory values in-
cluded a platelet count of 279,000 and an LDH of
775 (normal range 313-618 IU/1). The prothrombin
time (PT) and partial thromboplastin time (PTT)
were 10.3 and 29, respectively (normal range PT
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11.1-14.7 sec, PTT 20-33 sec). A right upper-quad-
rant ultrasound demonstrated normal gallbladder
anatomy with no evidence of cholelithiasis. The
admission nonstress test was reactive. The differen-
tial diagnosis included infectious hepatitis, severe
preeclampsia, fatty liver of pregnancy, autoimmune
hepatitis, and Wilson’s disease.
Hepatitis A and B testing was negative, as was
herpesvirus IgM. The serum ceruloplasmin, ANA,
iron, and ferritin were normal. A hepatitis C anti-
body was ordered, but the results were not immedi-
ately expected. The 24-h urine protein was 324
mg, with a creatinine clearance of 143 ml/min. An
amniocentesis was performed on the day of admis-
sion to assess the need for steroids to enhance the
fetal lung maturity. The amniocentesis was per-
formed prior to the deterioration in the maternal
hepatic function. The values revealed a lecithin/
sphingomyelin ratio of 2.2, with phosphatidyl glyc-
erol present. The amniotic-fluid glucose was 26 rag/
dl. An ultrasound demonstrated a singleton preg-
nancy in a breech presentation with an estimated
fetal weight of 2,213 g.
On hospital day 4, the patient’s PT rose to 11.2,
with an International Normalized Ratio (INR) of
1.3. With the rising PT in the presence of docu-
mented fetal lung maturity, the patient was offered
delivery by a primary cesarean with an intraopera-
tive liver biopsy. A cesarean delivery was offered
for the breech presentation. The neonate weighed
2,128 g, with Apgar scores of 8 and 9.
The patient’s postoperative course was compli-
cated by a slow resolution of her hepatic dysfunc-
tion. The liver biopsy demonstrated active hepatitis
with necrosis but no fatty infiltration. The serum
hepatitis C antibody by enzyme-linked immunosor-
bent assay (ELISA) was positive when the results
returned 5 weeks post-delivery, having been sent
to an outside reference laboratory with slow turn-
around time. The liver biopsy also demonstrated
HCV RNA by the polymerase chain reaction (PCR)
method. Her husband was HCV negative by
ELISA. One year after delivery, she demonstrated
chronic active hepatitis, with the AST persisting at
115-120 and ALT at 160-165.
was successfully controlled with nasal packing, a
physical examination revealed a morbidly obese fe-
male whose spleen edge was 4-5 cm below the left
costal margin. Her laboratory values were significant
for normal hemoglobin and hematocrit, but a plate-
let count of 81,000. The PT was 16.4 with an INR
of 1.6, and the PTT was 46. The liver enzymes
included an AST of 92, ALT of 75, and total biliru-
bin of 0.9. An abdominal ultrasound revealed the
spleen to measure 17.4 cm in superior-to-inferior
dimension. Upon further questioning, the patient
stated that she had a longstanding history of intrave-
nous (IV)-drug abuse, but had not used drugs in
this fashion for several years. However, she did state
that she had episodes of "binge" drinking in which
she consumed at least a quart of beer at a time. Her
most recent episode had occurred 4 days prior to
her admission. Severe portal hypertension was sus-
pected based upon the above findings, with signifi-
cant platelet sequestration in the maternal spleen.
A workup for autoimmune liver disease, antiphos-
pholipid antibody disease, hemochromatosis, and
Wilson’s disease was negative. The patient had a
positive 4-recombinant immunoblot assay (4-RIBA)
forHCV with antibodies detected against 4 antigens
encoded by different parts of the HCV genome.
Despite several more episodes of epistaxis, the only
other complication during the remainder of her
pregnancy was insulin-requiring gestational diabe-
tes. At 38 weeks gestation, an induction of labor was
offered. On the day of her admission, the laboratory
values included a PT of 16.7, PTT of 46, and plate-
let count of 94,000. When the active phase of labor
was achieved, the patient was given 2 units of fresh-
frozen plasma. At the time of complete cervical
dilation, she was given 6 units of platelets. Clotting
factors were administered because of her increased
risk for postpartum hemorrhage as well as bleeding
from the suspected esophageal varices. After a pas-
sive second stage (minimal maternal pushing ef-
forts), she had a spontaneous vaginal delivery of a
viable 4,341-g female infant. There was no obstetric
hemorrhage or rupture of the esophageal varices
during delivery. The cord blood obtained for deter-
mination ofHCV RNA status was negative by PCR.
Case 2
The patient was a 3S-year-old G3Pz00z who presented
to the emergency room with severe epistaxis at 17.5
weeks estimated gestational age. After the bleeding
DISCUSSION
In 1989, the genome of HCV was cloned, and an
assay was developed to detect the presence of anti-
bodies directed against this agent. Subsequently,
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 249HCV IN PREGNANCY JOFFE
with the use of radioimmunoassay (RIA), ELISA,
and RIBA, it was demonstrated that approximately
88-90% of post-transfusion non-A, non-B (NANB)
hepatitis is associated with hepatitis C infection, z’3
The incidence of NANB, most of which is ac-
counted for by HCV, has been reported as 7.1 per
100,000 cases. This RNA virus has not yet been
visualized. The incubation period is 7 weeks, and
the mean time interval between transfusion and
anti-HCV seroconversion is 16-22 weeks, z’3 Trans-
aminase levels range from 450 to 2,000 IU/I. The
mean length of time for an elevation of transami-
nases in patients with resolving hepatitis has been
reported as 8.2 weeks. The bilirubin levels are
significantly elevated in over 75% of patients. The
mortality rate following the acute onset of the dis-
ease has been reported as 1.6%. An estimated 40-
60% oftransfusion-associated HCV infections result
in chronic disease, with 20-40% eventually devel-
oping cirrhosis. The combination ofchronic alcohol
exposure and HCV infection results in significantly
greater liver injury evident on histologic examina-
tion than the presence of alcohol exposure alone.
Several factors have significantly decreased the
incidence of transfusion-associated HCV infection.
These include testing blood donors for levels of
ALT as well as antibody to hepatitis B core antigen,
which started in 1986. Screening for human immu-
nodeficienc virus infection also contributed to the
decline. Screening of potential blood donors along
with a significant increase in IV-drug abuse in asso-
ciation with HCV infection between 1984 and 1989
has led to the conclusion that most cases ofNANB
hepatitis in the United States are not transfusion
related. Approximately 45-50% ofNANB hepatitis
are associated with IV-drug abuse. Blood transfu-
sion accounts for as few as 2% of cases. Household
contacts of infected individuals represent 10-15%
of the patients with HCV infections. The source of
infection is unidentified in roughly 35% of cases;
case-control studies have demonstrated a significant
association with multiple sexual partners in the het-
erosexual population.
Screening for HCV infection is usually carried
out in two steps. The ELISA, a somewhat nonspe-
cifi assay for anti-HCV antibody, is the first step
in the screening process. Over half of those found
to be positive on the ELISA screen will prove to
have false-positive results when the more specific
4-RIBA is carried out. This assay requires that at
least 2 of 4 HCV antigens be present, as demon-
strated by antibody reactivity. The 4-RIBA has
demonstrated a strong correlation with the PCR
determination of HCV sequences in the sera of
patients with post-transfusion NANB hepatitis.
In 1989, it was demonstrated that many patients
who developed fulminant infectious hepatitis were
completely lacking in endogenous interferon pro-
duction. In an uncontrolled trial, these investiga-
tors suggested that treatment with human inter-
feron alpha decreased the mortality associated with
severe disease resulting in hepatic coma. This series
included 3 pregnant patients. Two of these 3 pa-
tients survived.
Maternal-to-infant transmission of HCV is
thought to occur less frequently than with HBV
infection. However, the recent literature suggests
a strong positive correlation between the level of
maternal viremia at the time of delivery and the
incidence of HCV infection in the infant. The de-
gree of clinical disease, in other words, chronic ac-
tive hepatitis vs. chronic persistent hepatitis, is also
predictive of transmission to the offspring of in-
fected mothers. Although the number of mother-
infant pairs studied is limited, the generally quoted
risk for the vertical transmission of HCV is 5-10%.
Presently, there are no tests available to detect the
presence of HCV antigen in the serum. Therefore,
it is not possible to determine level of infectivity
as in the case ofhepatitis B infection where hepatitis
B e antigen can be assayed. The PCR for amplifica-
tion ofcomplementary nucleotide sequences to por-
tions of the viral genome is still not available in
most hospital laboratory settings. Furthermore, a
single negative PCR examination does not elimi-
nate the possibility of HCV infection, as titers of
viral nucleic acids fluctuate widely throughout the
course of the chronic disease. The role of
breastfeeding in the transmission ofHCV is incom-
pletely defined, although transmission by this route
has been described.1
Case 1 demonstrates that fulminant hepatitis sec-
ondary to HCV infection can occur in pregnancy.
This patient was typical in that the source of her
exposure could not be identified. Unfortunately,
she became of the 40-60% of patients developing
chronic hepatic dysfunction. Case 2 demonstrates
the severe hepatic destruction that can occur when
a patient with persistentHCV replication adds etha-
nol intake to the equation. Indeed, a significant
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population of patients requiring liver transplanta-
tion in the United States present with both of these
environmental exposures as etiologies for their dis-
ease. With the severity of her disease, this patient
was fortunate in that she did not manifest vertical
transmission of the HCV agent.
In conclusion, pregnancy-associated HCV infec-
tion may present as a mild, self-limited disease,
chronic disease, or fulminant hepatitis. Most infec-
tions are not sequelae of blood transfusions but
more often associated with IV-drug abuse. Although
the HCV antigen cannot yet be demonstrated in
serum, antibody testing by ELISA with confirma-
tion by the 4-RIBA method is now readily available.
Vertical transmission may be demonstrated by the
presence of viral RNA sequences using PCR tech-
niques.
Primary-care obstetrician-gynecologists can ex-
pect to manage patients with subclinical but persis-
tent HCV infections, either during pregnancy or
during routine gynecologic care. As such, these phy-
sicians must be aware that a high percentage of
patients develop chronic hepatic dysfunction and
that alcohol consumption significantly accelerates
the disease process. In addition, patients should be
aware that, at the present time, interferon is the
mainstay of therapy in the presence of chronic ac-
tive disease.
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